Tumor Size and Sentinel Node Procedure
description
Transcript of Tumor Size and Sentinel Node Procedure
Tumor Size and Sentinel Node
Procedure
A. Ph. MAKAR, MD, Ph.D.
R. Van Den Broecke, MD, Ph.D.
Depart of Senology & Gynaecologic OncologyThe Middelheim Hospital
University Hospital of Ghent
Tumor size
I. Carcinoma in situ II. T1 & T2 (<3cm ) tumorsIII. Large T2 & T3 tumorsIV. Inflammatory breast cancerV. Multi-centric / multi-focal disease
Prospective analysis Middelheim hospital 1998-2001, 268 patients, single surgeon
Sense of SN procedure
• Impact on further surgical management, postoperative treatment or prognosis
• False negative rate: acceptable
• Number to be saved complete ALND: high
• Number that needs second surgery: low
– increased morbidity: swelling, numbness, pain– increased coasts– completeness of axillary dissection ?
I. Ductal Carcinoma In Situ
• Silverstein: rate of axillary metastases < 1%
• Survival rate > 98%
• Axillary staging is generally not necessary
• IHC: micro-metastases in 5-15% of cases • Lara (2003) & Broekhuizen & Marby (2006):
– No impact on local failure or distant metastasis
ADH/DCIS in core biopsy: underestimation risk
• Underestimation risk of invasive
disease : 20-40%• SN procedure can be justified:
– Mammographic lesion >5cm– Underlying mass/distortion – Palpable lesion & Core biopsy under
sonography– High grade lesion & micro-invasion &LVSI
II. T1 &T2 tumors (<3cm)
• Extensive evaluation: ASCO guide lines
• Identification rate >95%– Failed identification:
• Age >60 years
• Capsular invasion, high number of positive nodes
• FNR <10%: removal of all radioactive nodes
• IHC: more micro-metastases 15% (10-67%)
• SN metastases in <50% of tumors
• SN only site of metastases in 40%
Positive SNmacro-metasmicro-metas
Complete ALND Alternatives ? ?
Radiotherapy Observation(EORTC) ACSOG00Z11
Historical NSBAP-04
Micro-metastases in SN: Risk factors predicting Non-SN metastases
• LVSI
• Tumor size
• Extra-nodal spread
• Micro-metastasis:– Size of micro-metastasis– Micro-metastasis detected by HES vs IHC– Location of micro-metas: sinusal vs intranodal
• Number of pos SN/total nr of SN: (1/3)
Rate of Non-SN involved in case of micro-metastases in SN according to tumor size
Tumor size (mm) Involved Non-SN %
0-5
6-10
11-20
0-20
21-50
>50
4.8%
8.2%
15.3%
13.4%
30.8%
50%
T1 tumors & micro-metastasis in SN
Houvenaeghel (2006) & Leikola (2006):
• pT1a, pT1b (IHC)
• pT1a- pT1c of tubular, colloid or medullary types– Risk of Non-SN involvement: <5%– Risk of involvement of >1 Non-SN : 0%– ALND can be omitted with minimal risk
Prediction of Non-SN metastases in case of micro-metstases in SN
• Turner (2000): likelihood model
• Van Zee (2003): nanogram (9 variables)
• Meta-analysis:– No combination of factors was able to predict
non-SN metastases – 10% of the micro-metastases in the SN were
associated with one or more macro-metastases in Non-SN
ALND dissection is recommended in every case with micro-metastases in the SN
The prognostic significance micro-metastases:
The Ludwig Breast Cancer Study Group
NSABP-32ACSOG Z0010
III. Large T2 & T3 tumors
Authors No SN LN False
pts identified metas neg rate
O’Hea (1998)
Winchester (1999)
Bedrosian (2000)
Cohen (2001)
Wong (2002)
Chung (2001)
Leidenius (2005)
Makar
25 82% 25%
31 90% 20%
104 99% 63% 2%
83 82% 58% 10%
59 100% 73% 4%
41 100% 76% 3%
70 95% 71% NS
106 82% 52% 2%
SN in tumors <=3cm vs >3 cmLeidenius 2005
<= 3cm > 3cm P value
Axillary metas %
Micro-metas/ITC %
Pos para-sternal SN %
AD omitted (neg SN)%
38%
38%
1.9%
T1a-b: 72%
T1c: 57%
71%
20%
2.8%
28.5%
<.0001
<.02
NS
<.001
% patients with tumors > 3cm and pos SN that have an additional disease in Non-SN
0%10%20%30%40%50%60%70%80%90%
100%
SNmicrometastasis
SNmacrometastasis
% patients
SN with T3 tumors
• The high risk of nodal metastases warrants complete ALND unless:– Motivated patient to have LN conservation
SN procedure following pre-operative CT: Meta analysis
• Identification rate (IR): 91% – IR isotope 95% vs 93% blue dye– No serious concern regarding the fibrotic effect of
CT on lymphatic pathways
• False negative rate: 12%
Neo-adjuvant chemotherapy & axillary downstaging
• Anthracyclin / cyclophosph based CT provides up to 30 % axillary down staging– Size of residual LN metastases after neo-adjuvant
CT is of prognostic significance
• Changing concept:– SN prior to neo-adjuvant CT followed by
“2nd look” axillary dissection post CT
= better prognostic information
Tumors >3cm with macro-metastases in SN
= almost 100% non-SN metastases
SN prior to CT (better staging)
Axillary dissection post CT
Pathologic remission Persistent disease
Less morbidity
IV. Inflammatory breast cancer
• Insufficient data.
• High risk of nodal spread
• False negative rate:– Occlusion of subdermal lymphatics (tumor
emboli)
V. Multicentric tumors
• Occurs in up to 10% of cases
• Were excluded by most SN investigators
• Hypothesis “sentinel for the entire breast”:– High success ratio– No increase in false negative ratio– Peri-areolar injection
Increased risk of nodal metastases with multi-focal tumors
Tumor size (mm)
Uni-focal Multi-focal
( 877 tumors) (107 tumors)
1-10
11-20
21-30
>30
22% 45%
37% 51%
53% 72%
68% 100%
Conclusions-1
• DCIS: – In some cases of core biopsy with risk of
underestimation:• Lesions > 5cm
• Underlying lesion: density/distortion
• High grade tumors & micro-invasion, LVSI
• Immediate reconstruction
Conclusions-2
• T1 –T2 (< 3cm):– Standard procedure with N0– With few exceptions “T1a and T1a-T1c of certain
pathology”, a full ALND is indicated in case of microscopic disease in the SN
– The prognostic significance of micro-metastases needs further evaluation
Conclusions-3
• Large T2 & T3 tumors:– IR and FNR are comparable with T1 tumors– Yet the high incidence of LN metastases makes
the clinical relevance of SN procedure of limited value except in case of neo-adjuvant CT
• Multi-centric /multi-focal disease: – More reports suggest safety of the procedure– Yet multifocal tumors have higher risk of nodal
spread than unifocal ones of same diameter
Conclusion-4
• 2nd axillary surgery carries more morbidity:
Prospective multi-centric trial comparing immediate versus “second-look” axillary surgery post chemotherapy in patients with positive SN:
Welcome to participate
Sentinel Node Team
• Nuclear medicine:– K. Melis
– F. Van Acker
• Pathology:– S. Declercq
– L. Van Leuevn
– C.Mattelaer
• Radiotherapy:– D. Van denWeyngaert
– S. Vanderkam
– I. Jacobs
• Medical Oncology– E. Joossens
– D. Becquart
– A..Vandebroek